Posts Tagged ‘Tampa’
The Claimants’ Advisory Committee (CAC) is the official committee appointed by the U.S. District Court in the Eastern District of Michigian to represent the interests of women in the Dow Corning Bankruptcy Settlement Plan. They have a website with information concerning the Settlement Facility for the Dow Corning Trust (SF-DCT).
Phone Number: 419-394-0717
Email address: email@example.com,
Mailing address: Claimants’ Advisory Committee, P.O. Box 665, St. Marys, OH 45885.
You can also sign up on the website to receive a free copy of their monthly electronic newsletter by e-mail.
LATEST COURT ORDERS ON THE WEBSITE
July 31, 2014 – 6th Circuit Court of Appeals affirmed that tissue expanders are included in the definition of “Breast Implants” June 20, 2014 – Stipulation and Order Recommending the Appointment of the Honorable Pamela R. Harwood as Lien Judge March 31, 2014 – 6th Circuit Court of Appeals ruled Denying Dow Corning’s Motion to Stay Partial Premium Payments February 25, 2014 – Order Denying Motion to Stay Pending Appeal.
LINKS TO RELATED WEBSITES
Settlement Facility website: www.dcsettlement.com
Email address: firstname.lastname@example.org
Mailing address: Settlement Facility – DC Trust P.O. Box 52429 Houston, TX 77052-2429
Phone Number: (713) 874-6099
Toll free Phone Number: (866) 874-6099 (within the U.S.)
International Toll Free Number AT&T Direct Access Number: + 866 + 874 6099 (outside the U.S.)
MDL 926 Claims Office for the Revised Settlement Program:
Website: www.fjc.gov (MDL 926 Court)
Website: www.claimsoffice-926.com (MDL 926 Claims Office) The MDL 926 Claims Office website is still under development, so some “headings” do not have any information listed. Additional information will be posted as it becomes available.
Email address: email@example.com
Mailing address: MDL 926 Claims Office P.O. Box 56666 Houston, TX 77256
Phone Number: 1-800-600-0311
United States District Court for the Eastern District of Michigan
Website address: www.mied.uscourts.gov
For a Dow Corning Breast Implant Lawyer contact the Dow Corning Breast Implant Helpline
Our lawyers are private practice lawyers. They are not employed by or affiliated with the Dow Corning Claims Settlement Office. If you hire one they are your advocates for you.
Breast Implant Lawyers Accepting Dow Corning Breast Implant ClaimsOur Breat Implant lawyers are reviewing Dow Corning Breast Implant Claims for women implanted with Dow Corning implants prior to June 1, 1993 and who are registered with the SF-DCT.
We are here to help with your Dow Corning silicone breast implant claims and will connect you with a female silicone breast Implant lawyer who has been helping women for 2 decades. Our lawyers have helped women obtain settlements for breast implant diseases such as Lupus, Scleroderma and General Connective Tissue Diseases.
DECEMBER 3, 2015
The District Court issued an Order approving the Consent Order To Establish Guidelines for Distributions From The Class 7 Silicone Material Claimants’ Fund. This means that the Court has authorized approved disease claims in Class 7 to be paid and has approved the parties’ agreed interpretation of “marshaling.” The order will become final once the 30-day time period for appeals has expired and no appeals have been filed. Payments can begin once the Order is final. This means that payments will not begin until sometime in January 2016 or thereafter.
DECEMBER 1, 2015
Copy of the SFDCT letter sent to claimaints with an approved Disease Option 2 claim regarding Increased Severity – Please note the deadline date of June 2, 2019 is incorrect. The correct deadline date is June 3, 2019. To read the response, click here.
SEPTEMBER 15, 2015
Omnibus Response to Objections & Submissions Responding to Consent Order to Establish Guidelines for Distribution From Class 7 Silicone Materials Claimants Fund. To read the response, click here.
JULY 29, 2015
Scheduling Order Regarding Consent Order to Establish Guidelines for Distributions from Class 7 Silicone Material Claimants’ Fund. To read the order, click here.
JULY 17, 2015ATTORNEYS:
Wells Fargo, the paying agent for the SF-DCT, requires law firms to provide an updated w-9 before payment can be issued. You can download a copy of the updated w-9 form here. Please complete and return the w-9 to the SF-DCT.
JUNE 12, 2015
Copy of the Notice to Class 7 Claimants Establishing Guidelines mailed by the SFDCT. To read the notice, click here.
JUNE 2, 2015
Judge Hood as issued an Order Authorizing Distribution of the Notice in reference to the Class 7 Consent Order. To read the order, click here.
MAY 26, 2015
CAC FILES MOTION ASKING FOR APPROVAL TO PAY CLASS 7 CLAIMS AND TO RESOLVE THE DISPUTE CONCERNING PREVIOUSLY DENIED “MARSHALING” CLAIMS
On Friday, May 22, 2015, the CAC filed a proposed Consent Order asking the Court to authorize payment of disease claims for Class 7 claimants. Most claimants in Class 7 have been previously paid a $600 Expedited Release Payment, a Foreign Gel Claimant Payment, or a $3,000 Cash-Out Offer. Claimants that rejected the Cash-Out Offer and elected for a full disease review have been waiting for payment on their approved disease claim. With the filing of the motion, the CAC hopes that these claimants can now be paid once the Consent Order is entered by the Court.
In addition, the CAC has reached an agreement with Dow Corning regarding thousands of Class 7 claims that were previously denied by the SF-DCT on the grounds that the claimant allegedly had not “marshaled” their recoveries from their primary manufacturer (Bristol, Baxter). Under this agreement, claims will be reviewed to determine if the claimant was eligible to apply for disease compensation from the Revised Settlement Program. If so, then that claimant cannot apply for the same disease in Class 7. However, if a claimant was not eligible to receive benefits for a particular disease in the RSP, then that claimant may seek compensation from Class 7.
For example, if a claimant was an Other Registrant in the RSP, the only disease option she was eligible for was Disease Option 2 (called Long Term Benefits). Other Registrants were not eligible for Disease Option 1 (Fixed Benefits) and diseases like ACTD. These claimants may now seek compensation for Disease Option 1 from Class 7.
The SF-DCT will re-review the claims that were previously denied and will send eligible claimants either a $600 Expedited Release Payment or $3,000 Cash-Out Payment. The Cash-Out Payment is available only to those claimants who submitted a disease claim in 2006. Claimants may reject the Cash-Out Payment and instead elect for a full disease review; however, if the claim is not approved, they will not be eligible for the Cash-Out Offer again.
MAY 4, 2015
The MDL Common Benefit Trust fund has announced that it will offer women who were not compensated for Explantation in either the MDL or Dow Corning Settlement a chance to apply for $5,000 explant payment. For more information about this program, please click here. Please note that this program is not affiliated with either the RSP or Dow Corning Settlement Plan.
If you are having difficulty getting your medical insurance to cover the cost of the explant surgery, there is a new resource for women. The Insurance Coverage Assistance Program will be available to provide advice and assistance on how to assess this Medicare, Medicaid, and health care coverage for issues related to breast implants. This program is to be operated by the National Center for Health Research, a consumer-oriented non-profit group in Washington, D.C., that has helped women seek insurance coverage for breast implant removal. The National Center currently operates the breastimplantinfo.org website. You may email them at firstname.lastname@example.org with your name and email address for more information, including their toll-free number. If you do not have access to email, you can call them at 202-223-4000.
FEBRUARY 10, 2015
On January 27, 2015, the Court of Appeals reversed the District Court’s authorization to make 50% partial Premium Payments. Fortunately, the SF-DCT has already made 98% of the partial Premium Payments to eligible, approved claimants. This money does not need to be repaid. Claimants can keep the partial Premium Payment checks that were issued to them. Unfortunately, the remaining 2% of claimants who did not receive their partial Premium Payment check (or returned it for reissuance, or who had lost checks) are on hold pending either a consensual resolution to pay their claims or a court order. A copy of the ruling is under the tab “Court Orders.”
February 10, 2015,
CAC filed a petition for rehearing on this ruling, asking the Court of Appeals to reconsider or rehear the issue based on what the CAC believes are two serious legal errors. A copy of the petition is under the tab “Appeals to the 6th Circuit” and then under the sub-tab “Premium Payments.”
IF YOU NEED HELP WITH YOUR DOW CORNING BREAST IMPLANT CLAIM CONTACT US TODAY
News Regarding the Dow Corning Expedited Release Checks
The Settlement Facility Dow Corning Trust has recently decided to send Expedited Release Payments in the amount of $2,000 to all Dow claimants whose cases are idle.
Important Information Regarding Accepting This Offer
Be aware that if you accept this payment you can NEVER apply for a disease claim in the future, even if you become sick.
What Should I Do Id I Receive An Expedited Release Check?
If you receive an expedited release check in the mail, you should not cash it. Call us to speaker to a Dow Corningg Breast Implant lawyer to make sure you are doing the right thing.
Dow Corning Settlement Alert
If you cash the expedited release check you will be agreeing to settle your claim and can never get any additional funds.
The Vaginal Mesh, Bladder Sling Lawsuits
Pelvic mesh lawsuits have become the next big massive run of lawsuits for women injured by these devices. This looks like it will surpass the Dow Corning Breast Implant Class Action
What Is The Vaginal Mesh Or Bladder Sling?
Prolene mesh is a medical implant used to reinforce weakened or damaged pelvic muscle. The result of a weakened pelvic floor is organ prolapse or urinary incontinence . These mesh implants involved in the lawsuits are made from a synthetic material.
The Lawsuits Start With A Warning From The FDA
On July 13th, the FDA issued an Alert stating that serious complications associated with vaginal mesh/bladder slings for transvaginal mesh implants are not uncommon. This is the date when for the time clock statute of limitations for your state starts ticking.
What are the Vaginal Mesh or Bladder Sling Side Effects The Transvaginal Mesh Lawsuits Allege?
The Florida Fort Lauderdale, Miami, West Palm Beach, Orlando, Tampa, Ft Myers, Jacksonville transvaginal mesh side lawsuits allege that women victims are experiencing injuries that could have been avoided had these women been given the proper information and the devices had the right pre market testing.
Florida Women Are Angry And The Want To Sue The Mesh Manufacturers
Fort Lauderdale, Miami, West palm Beach, Orlando, Tampa, Ft Myers, FL Mesh Sling Helpline is hearing from women wanting to get the lawsuit information and file a Pelvic Mesh lawsuit against Bard, Boston Scientific, Johnson and Johnson, AMS and Coloplast who are the mesh manufacturers. Infections, more incontinence, extreme pain during intercourse, UTI, back pain, inability to walk, and severe relentless pain are rampant in mesh implant victims.Some of these infections spread through the whole body and lead to death. Sometimes the vaginal mesh side effects can up to 7 years to develop after the initial surgery.
The Lawsuit Answers These Demands
The Fort Lauderdale West Palm Beach, Boca Raton, Jacksonville, Tampa, Sarasota , FL Mesh Lawsuit a continues to claim hat there are other safer alternatives to synthetic mesh (biological mesh for example) that should be considered before the decision is made to use synthetic materials.
Florida Mesh Lawsuits Consolidated
Fort Lauderdale, West Palm Beach, Miami, Orlando Tampa FL Pelvic Mesh Lawsuits Have Been Consolidated in an MDL litogastion in West Virginia.
Vaginal Mesh Multi District Lawsuits Have Been Consolidated Under Judge Goodwin in West Virginia
Vaginal mesh lawsuit MDL – 2325, IN RE: American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation
Vaginal mesh lawsuit MDL – 2326 IN RE: Boston Scientific Corp. Pelvic Repair System Products Liability Litigation
Vaginal mesh lawsuit MDL – 2327 IN RE: Ethicon, Inc., Pelvic Repair System Products Liability Litigation
Vaginal mesh lawsuit MDL – 2387 IN RE: Coloplast Corp. Pelvic Support Systems Products Liability Litigation
Vaginal mesh lawsuit Cook Medical Surgical will be the fifth MDL
Call our new Transvaginal mesh Lawsuit Lawyers help Department and file your pelvic mesh lawsuit today
Right now bellwether trials are underway for vaginal mesh lawsuits. Thousands of women have suffered from these vaginal mesh devices. Our new vaginal mesh department has a vaginal mesh lawsuit lawyer for you.
VAGINAL MESH AND RELATED BLADDER MESH PRODUCTS ARE THE BIGGEST PANDEMIC EFFECTING WOMEN Over 300,000 women are effected and so many have their own stories of pain and suffering,
Manufacturers of Mesh Products Include:
Johnson & Johnson,
Prolene Polypropylene Mesh Patch,
Avaulta Plus BioSynthetic Support System,
Avaulta Solo Synthetic Support System,
Pelvitex Polypropylene Mesh,
American Medical Systems or AMS,
Advantage Sling System,
Obtryx Curved Single,
Obtryx Mesh Sling,
Prefyx Mid U Mesh Sling System,
Prefyx PPS System,
The vaginal mesh Continues to effect women and alter the lives of 1000’s of women and their families.
If you or a loved one has a failed vaginal mesh and is ready
to stand up for justice call now to file a vaginal mesh lawsuit
Breast Implant Helpline keeps you updated on all breast implant news. Years after the Dow Corning Silicone Breast Implant disaster a new silicone breast implant hits the market. The FDA has approved a new silicone gel breast implant from Johnson & Johnson.
Next Generation breast Implant?
The Food and Drug Administration said it has approved a next-generation silicone breast implant from Mentor, a unit of New Brunswick-based Johnson & Johnson. Ladies let’s remember who this is. The same folks that bring you the vaginal mesh implant that is ruing lives nationwide. We watch with skepticism. The company’s MemoryShape breast implant uses a cross-linking gel design that the FDA says is firmer than previous implants. FDA regulators approved the new implant for breast enhancement and reconstruction in women at least 22 years old.
Can Silicone Breast Implants Make A Comeback?
Silicone gel implants have made a comeback recently after safety concerns kept them off the market for nearly 25 years.
The FDA banned sales of silicone breast implants in 1992, saying manufacturers had not provided enough medical data showing their safety and effectiveness. At the time, there were worries about a connection to a variety of diseases, including cancer and lupus. Alarming cases of ruptures added to the concern. Women are still waiting on settlements from the Dow Corning Class Actions and a new breast implant explant program has been announced.
The FDA said Friday it approved Mentor’s new implant based on studies tracking six years of data in 955 women. The agency said complications with Mentor’s MemoryShape implants were similar to those from previously approved silicone gel implants.
FDA is requiring Mentor to meet a number of requirements in connection with the new approval, including:
• Tracking the 955 women with the new implant
• Conducting a new study of 2,500 women who receive the new implant
• Evaluating women’s comprehension and perception of the implant’s labeling
• Analyzing any implants that are removed from women and returned to the manufacturer
More than one in five women who get implants for breast enhancement will need to have them replaced within five years, accord to an FDA analysis of company data released in 2011. Despite that relatively high failure rate, FDA regulators concluded that the silicone-gel implants are basically safe, as long as women understand they come with complications. Some critics of the implants say the failure rate may be even higher, since many women have dropped out of the company studies.
We will be watching.
You may have received a letter from the Dow Corning Trust explaining a Breast Implant explant program. For help in understanding your rights and to speak to a breast implant explant lawyer contact the Breast Implant Helpline today
There is a Breast Implant Explant Program Deadline
The final deadline to submit an Explant Claim to the SF-DCT is June 2, 2014. You must have acceptable Proof of Manufacturer before you can be considered for the Explant benefit. The Explant benefit is $5,000.00. To qualify for this benefit, you must have your Dow Corning implants removed and not replaced with silicone.
It can take six months or longer to schedule an explant surgery and to obtain the necessary medical records from your surgeon or hospital. If you are eligible to apply for this benefit, you should keep this deadline date in mind. Do not wait to discuss your explant surgery with your doctor. This should be done as soon as possible.
What Is Breast Implant Explant Surgery?
Breast explant surgery is mplant removal. Explant surgery is the process by which your breast implants are removed from the breasts. Depending upon the reason for the surgery, additional material may be removed.
Dow Corning Explant Benefits Notice
EXPLANT DEADLINE IS JUNE 2, 2014
The Settlement Facility will mail letters to Class 5 and 6 claimants on April 26, 2013 reminding them of the Explant Deadline of June 2, 2014.
What is the Explant Deadline? To be eligible for the $5,000 Explant benefit (Class 5 only), you must have your Dow Corning breast implant removed by June 2, 2014 and you cannot receive another silicone gel breast implant after that. To file a claim, you must submit the Explant Form and the operative statement from the Explant surgery. Only claimants in Class 5 and 6.1 (non-U.S. Dow Corning breast implant claimants) are eligible for the Explant Payment.
June 2, 2014 may seem like a long time away, but our experience has been that it often takes up to 6 months or more to schedule an appointment with your surgeon, schedule the surgery, and obtain the necessary medical reports (such as the Operative Report) to submit a claim by the deadline.
If your Dow Corning breast implant is not removed by June 2, 2014, then you cannot apply for the Explant benefit.There is still money available to help you remove your defective Dow implants. There is money available to help you remove your defective breast implants
There have been so many drugs and devices targeting women over the years with so many ending up in FDA warnings, recalls and resulting in lawyers in the courtroom arguing for justice for 1000's of injured women. To name a few; equal and maybe far surpassing the Dow Corning Breast implant Class Action is the Prolene vaginal mesh. This device, used by OB GYN's for urinary incotinence and uterine, bladder and bowel prolapse, has been falling apart in women. The result has been pain suffering and the destruction of lives and marriages.
The failing mesh can erode thru the vaginal wall or even into the bladder or bowel, The pain is relentless and infections are ongoing. Many women are having a difficult time finding sympathetic doctors to remove the mesh as urinary incotinence returns and re prolapse occurr.
Two others are both manufactured by Bayer Pharmaceuticals. Yaz birth control pills has warnings for blood clots in young women, strokes, pulmonary embolisms and deep vein thrombosis. The latest is the popular Mirena IUD. The Mirena can stay inplanted for up to five years but can gravitate or migrate and cause uterine and abdomen perforations. The stories of lives ruined goes on and on. Even the metat on metal hip replacements like the recalled DePuy and Stryker are more detrimental to women sdue to the smaller frames.
Every day we hear about more dangerous drugs and medical devices. Our T.V's are filled with lawyer ads seeking injured women. These products like Fosamax, birth control medications and uterine devices; the transvaginal mesh and metal-on-metal hip implants all focus on women as their market. Eventually these products end up with warnings, are recalled and are consolidated in a multi-district litigation to defend 1000's of harmed women. In some cases they are fatal.
These products we see lawyer ds for include: Yaz, Transvaginal Mesh, Mirena IUD, Fosamax, DePuy Hip Replacement and others are flashing cross our T.V screens " have you been injured by" "Call th law firm of….." We encourage women to file their lawsuits, not necessarily with the lawyer they see on T.V but with a qualified experienced class action lawsuit lawyer who understands the MDL process and has experience in these matters. Be sure the lawyer you choose is not just taking your case to get his piece off the top and sending it to a"buddy".
The Breast Implant Helpline's new mission is to help all women find justice against manufacturer who choose profits over accurate warnings, and direct you to a dangerous drugs and devices lawyer for women.
Dow Corning and the Silicone Breast Implant Controversy
posted by Handsome Devil on Wed, 01/04/2012 – 20:32
University of Wisconsin-Whitewater
1. What are some of the major factors that led to the Breast Implant Controversy?
Throughout the 1980s and 1990s, class-action lawsuits claimed that Dow Corning's silicone breast implants caused systemic health problems. The claims first centered around breast cancer, and then migrated to a range of autoimmune diseases including lupus, rheumatoid arthritis and various neurological problems. Ok
Even though Dow Corning has spotted the signs such as stakeholder complaints and various test reports in advance, they have not handled the problems ethically and have tried to manipulate information detrimental to themselves.
Here are a few issues we found in the article:
Ethically the company should have listened to the scores of questions from customers and their doctors about serious medical problems resulting from the use of its product; however, the company has not stopped producing the product or not done anything to improve the current situation for the stakeholder’s benefits – consumer health. Yes
Secondly, the company ignored the internal reports over lack of safety testing, as reported. The mammary task force raised a question that the product could cause “a bleed through” into surrounding tissue and the test result was still “inconclusive”, even in the new product tests the engineers didn’t make sure of the product safety. In spite of these facts, the company kept selling the product to the market.
Thirdly, the company has disregarded its social responsibility to lead its community. It seemed to limit its responsibility only within its legal responsibility in a case that its product breaks the rules. To make business ethics perfect in its community, it should take care about its full responsibility on its legal aspect and its moral ethics. The unbalanced ethics approach finally not only risked the stakeholder’s health but also increased social costs in its communities. Ok
Lastly, the top managers violated its fiduciary duty to its stakeholder even in facing the allegations that the company had hidden negative test results and lied to the public about the safety of its products. The board of the directors continued to manufacture and sell the product as well as to proceeded to fight customers who brought suit alleging injury. Ok
There are other key factors such as the competition etc that need to be discussed
2. What are the ethical issues and principals involved in this case? Who has acted the most and the least responsibility? Explain.
The main ethical issue of the article was whether or not breast implants, although potentially harmful to the body, should be on the market.
Since the 1960’s when Dow Corning used silicone to develop the first prototype of a breast implant, there have been ethical concerns that have not been resolved.
In the early 90’s, breast augmentation was the second most common cosmetic procedure performed by plastic surgeons, and the top money maker. Not only were breast implants important for reconstructive surgery, such as after an accident or cancer treatment, but the demand for the implants was growing more rapidly as an elective procedure. There is even a growing medical opinion that micromastia, known as flat-chestedness, is a disease which can result in a patient having a total lack of body image and low self esteem. Thus, the enlargement is necessary to insure an improved quality of life for the patient. Ok
However, as the number of breast implant patients increased, so did the number of complaints. There were allegations of the implants causing pain, scarring, and even debilitating autoimmune diseases in the patients. But how was a product that was clearing injuring patients allowed to be on the market? How ethical was it to allow these products to be so available, and yet, so potentially dangerous? Yes
First of all, breast implants were not governmentally regulated when first developed in the 1960’s. FDA could not require approval for safety and effectiveness before products were on the market.
Second, in accordance with “good manufacturing” practices, Dow Corning did attempt to determine safety of medical products before releasing them to the public. However, the determination of “safety” was vague and based on the company’s opinion. When tested on animals, silicone was injected into the body. There was clear evidence of chronic inflammation; however, because the silicone would not be injected into humans, the finding was ignored.
Third, the new and improved implants were brought into the market quickly without extensive medical testing. The reasoning for this was because similar substances had already been tested in other facilities. It was; however, brought to the attention of Dow Corning that “bleed throughs” were occurring. The company assigned a few employees to investigate (meanwhile still providing breast implant procedures). They found that the bleeding was “no greater than what we measure from old control gels”. However, it was stated that these tests were “inconclusive”, and were never researched again. Ok
Finally, in 1975, it was found that the reject rate at inspection was as high as 50% on some production lots. And yet, the implants were still available on the market.
Need to also integrate some theoretical perspective to assess Dow’s egoism + utilitarian principles
The responsibility for these ethical issues is a combination of both the Dow Corning company and the government. The Dow Corning company, although not held to any level of standards, was providing a potentially harmful product to the public. Yes Testing was done, but was not conclusive. The government (FDA) allowed companies, like Dow, to supply harmful products because they did not require extensive testing. It was not until 1989 when the FDA finally identified silicone implants as Class III devices, meaning riskiest. But still, after many hearings, breast implants were cited as a “public health need” and were left on the market.
Plastic surgeons and the public also hold some responsibility. Surgeons, although knowledgeable about the possible effects, still recommended and used the products on their patients. Many breast cancer advocacy organizations and satisfied recipients also supported Dow Corning and the use of breast implants. Ok
3. What was the role of the US Food and Drug Administration? Should they take some blame for the scandal? Should they have taken a more active role early in the controversy? Is the role government agencies can play in this respect limited?
In the early years of the product, the Food and Drug Administration (FDA) had very little oversight of silicone breast implants. The FDA did regulate products meant for ingestion (pharmaceutical drugs) since 1906 (Pure Food and Drug Act) but implants were considered medical devices and outside the FDA’s regulatory scope. The products could be removed from the market only if the manufacturer was proven to break the law. Despite the Medical Amendments Act to the Food and Drug Act (1976) the FDA didn’t label breast implants as dangerous until 1989 (after numerous lawsuits). Ok
The FDA should have taken an active role to regulate these products and can be considered somewhat responsible. Dow Corning was able to put a new product designed for internal human use into the market with little testing and no oversight. Their testing revealed health dangers that they ignored and kept from the public. If the product was regulated, the FDA would have seen the effects on laboratory animals – the Silicon causing inflammation as it sticks to various organs and lymph nodes. Despite intent to keep the silicon out of the body, ruptures or leaks would cause damage and users at least need to be aware of the risk before putting the product inside their bodies. Regulation would have revealed the numerous red flags (animal testing, plastic surgeons’ trade show) associated with Dow Corning’s implants and their FDA approval would have been delayed until the problems were solved. Yes
Dow Corning and other corporations have the goal of making profits and increasing their shareholders’ wealth. The FDA and other government agencies should realize this and put checks in place to ensure these companies offer safe products and services. Breast implants may not be a food or a drug but they are meant for internal use in the human body and they should have been added to the regulatory scope of the agency much earlier than they were. One of the roles of government is to protect its citizens (national defense, criminal justice, health care) and while it is often hesitant to regulate business (especially when that business makes significant contributions to political campaigns) when blatantly dangerous products are made available to consumers, the government does have and should use its authority to regulate and prohibit sales of these devices.
4. Why did Dow’s exemplary formal code of conduct fail in preventing the controversy? What can be done to make a Code of Ethics more effective?
Dow’s exemplary formal code of conduct failed because its implementation was flawed and didn’t address all ethical issues, most important being safety. With great diligence they fought to make all business transactions legit, thus denouncing scandals which was admirable, but to avoid addressing safety as an ethical issue is not above reproach. The first ethical question raised should be “is the product we are manufacturing safe to the parties we are soliciting?” If studies are performed findings should be disclosed on the label and not hidden. Safety not being on the ethics score card made the formal code of conduct vulnerable to controversy. Ok To make a product that may have safety issues without proper notification to the parties involved is highly unethical. The employee’s at Dow involved in the safety studies as well as the top level managers that made the decision to push the product were quite aware of the situation. The urge to generate profit and regain market share took precedent over any safety concerns.
In an effort to make the Code of Ethics more effective, a company such as Dow’s must address all ethical issue’s leaving nothing to chance. To the fullest extent any possible ethical dilemma the company could face should be analyzed and given a proper course of action. Yes Granted no society lives in utopia, thus no Code will be perfect, but at no point should major issues such as safety be brushed under the rug to obtain a profit. Companies must also be willing to be honest with themselves in addition to the parties that they serve. Doing so not only makes it easier to create an effective Code of Ethics but also implementing it will come with ease. In the Dow’s case they were not being honest about the product they were promoting and selling. Stemming from the early stages they knew the product had potential to be a safety hazard but elected to forgo the proper testing to ensure the product wasn’t detrimental to an individual’s health.
Breast Implant Helpline can help you with your breast implant claim
Nationwide Breast implant helpline and Breast implant lawyers are helping women get compensation from the silicone Breast implant claims class action Recovery and compensation settlements.
Currently there are several class action lawsuits being filed by victims of defective breast implants.for Dow Corning, Mentor, Squibb, and others resulted in Lawsuits alleging such harm as cancer and autoimmune disease raked in millions of dollars throughout the 1990s, putting silicone breast implant manufacturers out of business or in danger of bankruptcy. With the assistance of “silicone doctors” who used minimal scientific evidence to support their claims, plaintiffs had stunning success. The wave of silicone breast implant lawsuits was largely a result of public opinion and aggressive pursuit of lawsuits by plaintiffs’ attorney, not medical evidence.
Dow Corning Brand Breast Implants Handled by Dow Corning Trust Facility (SF-DCT)
Settlements are currently handled for Dow Corning brand breast implants for Class 5 claimants as well as cases involving implants that contained silicone gel for Class 7 claimants. A product liability attorney will be able to explain the requirements for each of these defective breast implant lawsuits.
Funds are available for various foreign claimants and for those that received other Dow Corning manufactured products
The program offers settlement payments ranging from $2,000-$300,000 to eligible defective breast implant claimants until June 3, 2019.
The rules set up for breast implant litigation are very complex for the MDL-926, Revised Settlement Program and the Settlement Facility Trust of Dow Corning (SF-DCT). get help from a breast Implant helpline lawyer.
Speak to an experienced breast implant settlement attorney regarding defective breast implant claims or any other product liability cases for specific rules setup for product claims.
If you or a loved one are seriously injured or a death has occurred as the result of a defective breast implant or product, contact breast implant helpline and our breast implant lawyers to learn if you are entitled to legal compensation or have any questions regarding a breast implant registered claim.